Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Mucosal infection rewires TNFɑ signaling dynamics to skew susceptibility to recurrence.

Yu L, O'Brien VP, Livny J, Dorsey D, Bandyopadhyay N, Colonna M, Caparon MG, Roberson ED, Hultgren SJ, Hannan TJ.

Elife. 2019 Aug 20;8. pii: e46677. doi: 10.7554/eLife.46677.

2.

Host restriction of Escherichia coli recurrent urinary tract infection occurs in a bacterial strain-specific manner.

O'Brien VP, Dorsey DA, Hannan TJ, Hultgren SJ.

PLoS Pathog. 2018 Dec 13;14(12):e1007457. doi: 10.1371/journal.ppat.1007457. eCollection 2018 Dec.

3.

Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease.

Mydock-McGrane LK, Hannan TJ, Janetka JW.

Expert Opin Drug Discov. 2017 Jul;12(7):711-731. doi: 10.1080/17460441.2017.1331216. Epub 2017 Jun 2. Review.

4.

Bacterial virulence phenotypes of Escherichia coli and host susceptibility determine risk for urinary tract infections.

Schreiber HL 4th, Conover MS, Chou WC, Hibbing ME, Manson AL, Dodson KW, Hannan TJ, Roberts PL, Stapleton AE, Hooton TM, Livny J, Earl AM, Hultgren SJ.

Sci Transl Med. 2017 Mar 22;9(382). pii: eaaf1283. doi: 10.1126/scitranslmed.aaf1283.

5.

Evolutionary fine-tuning of conformational ensembles in FimH during host-pathogen interactions.

Kalas V, Pinkner JS, Hannan TJ, Hibbing ME, Dodson KW, Holehouse AS, Zhang H, Tolia NH, Gross ML, Pappu RV, Janetka J, Hultgren SJ.

Sci Adv. 2017 Feb 10;3(2):e1601944. doi: 10.1126/sciadv.1601944. eCollection 2017 Feb.

6.

A mucosal imprint left by prior Escherichia coli bladder infection sensitizes to recurrent disease.

O'Brien VP, Hannan TJ, Yu L, Livny J, Roberson ED, Schwartz DJ, Souza S, Mendelsohn CL, Colonna M, Lewis AL, Hultgren SJ.

Nat Microbiol. 2016 Oct 31;2:16196. doi: 10.1038/nmicrobiol.2016.196.

7.

Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections.

O'Brien VP, Hannan TJ, Nielsen HV, Hultgren SJ.

Microbiol Spectr. 2016 Feb;4(1). doi: 10.1128/microbiolspec.UTI-0013-2012. Review.

8.

Solving a Health Information Management Problem. An international success story.

Hannan TJ.

World Hosp Health Serv. 2015;51(2):32-5.

PMID:
26521384
9.

A Murine Model for Escherichia coli Urinary Tract Infection.

Hannan TJ, Hunstad DA.

Methods Mol Biol. 2016;1333:159-75. doi: 10.1007/978-1-4939-2854-5_14.

10.

Inhibition of Cyclooxygenase-2 Prevents Chronic and Recurrent Cystitis.

Hannan TJ, Roberts PL, Riehl TE, van der Post S, Binkley JM, Schwartz DJ, Miyoshi H, Mack M, Schwendener RA, Hooton TM, Stappenbeck TS, Hansson GC, Stenson WF, Colonna M, Stapleton AE, Hultgren SJ.

EBioMedicine. 2014 Oct 24;1(1):46-57. doi: 10.1016/j.ebiom.2014.10.011. eCollection 2014 Nov.

11.

Role of Hypoxia Inducible Factor-1α (HIF-1α) in Innate Defense against Uropathogenic Escherichia coli Infection.

Lin AE, Beasley FC, Olson J, Keller N, Shalwitz RA, Hannan TJ, Hultgren SJ, Nizet V.

PLoS Pathog. 2015 Apr 30;11(4):e1004818. doi: 10.1371/journal.ppat.1004818. eCollection 2015 Apr.

12.

Subinhibitory antibiotic therapy alters recurrent urinary tract infection pathogenesis through modulation of bacterial virulence and host immunity.

Goneau LW, Hannan TJ, MacPhee RA, Schwartz DJ, Macklaim JM, Gloor GB, Razvi H, Reid G, Hultgren SJ, Burton JP.

MBio. 2015 Mar 31;6(2). pii: e00356-15. doi: 10.1128/mBio.00356-15.

13.

Dysregulation of Escherichia coli α-hemolysin expression alters the course of acute and persistent urinary tract infection.

Nagamatsu K, Hannan TJ, Guest RL, Kostakioti M, Hadjifrangiskou M, Binkley J, Dodson K, Raivio TL, Hultgren SJ.

Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):E871-80. doi: 10.1073/pnas.1500374112. Epub 2015 Feb 9.

14.

Uropathogenic Escherichia coli superinfection enhances the severity of mouse bladder infection.

Schwartz DJ, Conover MS, Hannan TJ, Hultgren SJ.

PLoS Pathog. 2015 Jan 8;11(1):e1004599. doi: 10.1371/journal.ppat.1004599. eCollection 2015 Jan.

15.

Are you experienced? Understanding bladder innate immunity in the context of recurrent urinary tract infection.

O'Brien VP, Hannan TJ, Schaeffer AJ, Hultgren SJ.

Curr Opin Infect Dis. 2015 Feb;28(1):97-105. doi: 10.1097/QCO.0000000000000130. Review.

16.

Are doctors the structural weakness in the e-health building?

Hannan TJ, Celia C.

Intern Med J. 2013 Oct;43(10):1155-64. doi: 10.1111/imj.12270. Review.

PMID:
24134174
17.

Estrogen and recurrent UTI: what are the facts?

Hannan TJ, Hooton TM, Hultgren SJ.

Sci Transl Med. 2013 Jun 19;5(190):190fs23. doi: 10.1126/scitranslmed.3006423.

PMID:
23785033
18.

A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic Escherichia coli ST131.

Totsika M, Kostakioti M, Hannan TJ, Upton M, Beatson SA, Janetka JW, Hultgren SJ, Schembri MA.

J Infect Dis. 2013 Sep;208(6):921-8. doi: 10.1093/infdis/jit245. Epub 2013 Jun 3.

19.

Enterococcus faecalis overcomes foreign body-mediated inflammation to establish urinary tract infections.

Guiton PS, Hannan TJ, Ford B, Caparon MG, Hultgren SJ.

Infect Immun. 2013 Jan;81(1):329-39. doi: 10.1128/IAI.00856-12. Epub 2012 Nov 6.

20.

Distinguishing the contribution of type 1 pili from that of other QseB-misregulated factors when QseC is absent during urinary tract infection.

Kostakioti M, Hadjifrangiskou M, Cusumano CK, Hannan TJ, Janetka JW, Hultgren SJ.

Infect Immun. 2012 Aug;80(8):2826-34. doi: 10.1128/IAI.00283-12. Epub 2012 Jun 4.

21.

Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection.

Hannan TJ, Totsika M, Mansfield KJ, Moore KH, Schembri MA, Hultgren SJ.

FEMS Microbiol Rev. 2012 May;36(3):616-48. doi: 10.1111/j.1574-6976.2012.00339.x. Review.

22.

E-health in Australia: time to plunge into the 21st century.

Hannan TJ.

Med J Aust. 2011 Feb 21;194(4):211-2. No abstract available.

PMID:
21401473
23.

Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection.

Hannan TJ, Mysorekar IU, Hung CS, Isaacson-Schmid ML, Hultgren SJ.

PLoS Pathog. 2010 Aug 12;6(8):e1001042. doi: 10.1371/journal.ppat.1001042.

24.

The sustainability of Medical Morning Handover Reporting: adherence in a regional hospital.

Hannan TJ, Bart S, Sharp C, Fassett MJ, Fassett RG.

Aust Health Rev. 2010 Aug;34(3):325-7. doi: 10.1071/AH09820.

PMID:
20797365
25.

Now is the time for e-Prescribing.

Hannan TJ.

Intern Med J. 2010 Mar;40(3):242-3. doi: 10.1111/j.1445-5994.2009.02150.x. No abstract available.

PMID:
20446974
26.

Physicians need to understand the importance of information technology in the 21st century.

Hannan TJ.

Intern Med J. 2009 Oct;39(10):633-5. doi: 10.1111/j.1445-5994.2009.02030.x. No abstract available.

PMID:
19849754
27.

Readers' and author's responses to "Electronic personal health records: should doctors worry?".

Hannan TJ.

Medscape J Med. 2008;10(10):250; author reply 250. Epub 2008 Oct 31. No abstract available.

28.

LeuX tRNA-dependent and -independent mechanisms of Escherichia coli pathogenesis in acute cystitis.

Hannan TJ, Mysorekar IU, Chen SL, Walker JN, Jones JM, Pinkner JS, Hultgren SJ, Seed PC.

Mol Microbiol. 2008 Jan;67(1):116-28. Epub 2007 Nov 25.

29.

The AMPATH medical record system: creating, implementing, and sustaining an electronic medical record system to support HIV/AIDS care in western Kenya.

Tierney WM, Rotich JK, Hannan TJ, Siika AM, Biondich PG, Mamlin BW, Nyandiko WM, Kimaiyo S, Wools-Kaloustian K, Sidle JE, Simiyu C, Kigotho E, Musick B, Mamlin JJ, Einterz RM.

Stud Health Technol Inform. 2007;129(Pt 1):372-6.

PMID:
17911742
30.

A national survey of medical morning handover report in Australian hospitals.

Fassett MJ, Hannan TJ, Robertson IK, Bollipo SJ, Fassett RG.

Med J Aust. 2007 Aug 6;187(3):164-5.

PMID:
17680742
31.

Hope for HIV in Africa: observations by an Eldoret journeyman.

Hannan TJ.

MedGenMed. 2006 Feb 14;8(1):46. No abstract available.

32.

Donor-strand exchange in chaperone-assisted pilus assembly proceeds through a concerted beta strand displacement mechanism.

Remaut H, Rose RJ, Hannan TJ, Hultgren SJ, Radford SE, Ashcroft AE, Waksman G.

Mol Cell. 2006 Jun 23;22(6):831-42.

33.

A call for collaboration: building an EMR for developing countries.

Biondich PG, Mamlin B, Hannan TJ, Tierney WM.

AMIA Annu Symp Proc. 2005:894.

34.

An electronic medical record system for ambulatory care of HIV-infected patients in Kenya.

Siika AM, Rotich JK, Simiyu CJ, Kigotho EM, Smith FE, Sidle JE, Wools-Kaloustian K, Kimaiyo SN, Nyandiko WM, Hannan TJ, Tierney WM.

Int J Med Inform. 2005 Jun;74(5):345-55.

PMID:
15893257
36.

Installing and implementing a computer-based patient record system in sub-Saharan Africa: the Mosoriot Medical Record System.

Rotich JK, Hannan TJ, Smith FE, Bii J, Odero WW, Vu N, Mamlin BW, Mamlin JJ, Einterz RM, Tierney WM.

J Am Med Inform Assoc. 2003 Jul-Aug;10(4):295-303. Epub 2003 Mar 28.

37.
38.

The MOSORIOT medical record system (MMRS) phase I to phase II implementation: an outpatient computer-based medical record system in rural Kenya.

Hannan TJ, Tierney WM, Rotich JK, Odero WW, Smith F, Mamlin JJ, Einterz RM.

Stud Health Technol Inform. 2001;84(Pt 1):619-22.

PMID:
11604811
39.

The Mosoriot medical record system: design and initial implementation of an outpatient electronic record system in rural Kenya.

Hannan TJ, Rotich JK, Odero WW, Menya D, Esamai F, Einterz RM, Sidle J, Smith F, Tierney WM.

Int J Med Inform. 2000 Oct;60(1):21-8.

PMID:
10974639
40.

The Westmead Pediatric TBI Multidisciplinary Outcome study: use of functional outcomes data to determine resource prioritization.

O'Flaherty SJ, Chivers A, Hannan TJ, Kendrick LM, McCartney LC, Wallen MA, Doggett C.

Arch Phys Med Rehabil. 2000 Jun;81(6):723-9.

PMID:
10857513
41.

Detecting adverse drug reactions to improve patient outcomes.

Hannan TJ.

Int J Med Inform. 1999 Jul;55(1):61-4.

PMID:
10471241
42.
43.

Variation in health care--the roles of the electronic medical record.

Hannan TJ.

Int J Med Inform. 1999 May;54(2):127-36.

PMID:
10219952
44.

Relationships between symptom relief, quality of life, and satisfaction with hospice care.

Tierney RM, Horton SM, Hannan TJ, Tierney WM.

Palliat Med. 1998 Sep;12(5):333-44.

PMID:
9924596
45.

The electronic medical record: a missing component of the health information infrastructure in Australia.

Hannan TJ.

MD Comput. 1997 Mar-Apr;14(2):79-80, 82. No abstract available.

PMID:
9066241
46.

Introduction of a computer-based oncology patient-care system in a teaching hospital.

Hannan TJ, Vincenz M.

Med J Aust. 1988 Mar 7;148(5):242-7.

PMID:
3343955
47.

Enkephalins interfere with acquisition of an active avoidance response.

Rigter H, Hannan TJ, Messing RB, Martinez JL Jr, Vasquez BJ, Jensen RA, Veliquette J, McGaugh JL.

Life Sci. 1980 Feb 4;26(5):337-45. No abstract available.

PMID:
7366327
48.

Constant low-dose insulin infusion in severe diabetes mellitus.

Hannan TJ, Stathers GM.

Med J Aust. 1976 Jan 3-10;1(1-2):11-3.

PMID:
817112

Supplemental Content

Loading ...
Support Center